JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1092669, encodeId=de3010926697c, content=我是写那种格式的摘要比较好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092670, encodeId=030210926e030, content=摘要一般有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068169, encodeId=9c74106816911, content=偏重的研究方向：心血管;药物治疗 经验分享：请问这个杂志接受基础类研究吗？药物机制之类的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3e5463292, createdName=ms9000000616654220, createdTime=Mon Nov 08 17:13:16 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585267, encodeId=e24b58526e82, content=您好，请问您知道心血管类的网状meta分析应该投哪个杂志吗？王尛象 2018-10-25 00:00:00 发表: 10月23日晚上投的，10月25日下午被拒，理由是不再接收meta 分析类的。编辑挺友好地给回的邮件告知，做meta 的朋友就不必尝试了。, beContent=王尛象 2018-10-25 00:00:00 发表: 10月23日晚上投的，10月25日下午被拒，理由是不再接收meta 分析类的。编辑挺友好地给回的邮件告知，做meta 的朋友就不必尝试了。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=511d5270481, createdName=1482027dm93暂无昵称, createdTime=Mon Feb 24 00:00:00 CST 2020, time=2020-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579938, encodeId=17915e993842, content=请问需要版面费吗？多巴胺受体 2018-09-21 00:00:00 发表: 需要版面费吗, beContent=多巴胺受体 2018-09-21 00:00:00 发表: 需要版面费吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ba5226495, createdName=努力的科研小白, createdTime=Sat Nov 16 00:00:00 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562383, encodeId=9f4e562383a0, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：10月23日晚上投的，10月25日下午被拒，理由是不再接收meta 分析类的。编辑挺友好地给回的邮件告知，做meta 的朋友就不必尝试了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKJ73fWSxHh3xvG6CRmkSC454TlmZGCL5nXyJYuwwrvJtX7y37Q0W3jVTNKAXJvK0cZlXW85O4BdQ/132, createdBy=13532450097, createdName=王尛象, createdTime=Thu Oct 25 00:00:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561326, encodeId=ce2f56132633, content=需要版面费吗wgwang2003092 2016-08-20 22:19:00 发表: 投了一篇综述，审稿很快，审稿专家很友好！网刊更快！, beContent=wgwang2003092 2016-08-20 22:19:00 发表: 投了一篇综述，审稿很快，审稿专家很友好！网刊更快！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=287, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaELE8BUMzWSJdUBRwxgHrxk2iaPIB0NY8bDTJuSKseW0DVGuc7TAlMgB07cRxUAgPGp75ibOO3ItpezQ/132, createdBy=876d2299966, createdName=多巴胺受体, createdTime=Fri Sep 21 00:00:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=557427, encodeId=f52255e4276d, content=您好.想请教一下这个期刊的***址.找不到链接呀Lijia 2017-11-23 19:54:00 发表: 以下来自官网 Journal of Cardiovascular Pharmacology and Therapeutics 2016 Impact Factor: 3.000 2016 Ranking: 88/256 in Pharmacology & Pharmacy | 52/126 in Cardiac & Cardiovascular Systems Source: 2016 Journal Citation Reports? (Clarivate Analytics, 2017); Indexed in PubMed: MEDLINE, beContent=Lijia 2017-11-23 19:54:00 发表: 以下来自官网 Journal of Cardiovascular Pharmacology and Therapeutics 2016 Impact Factor: 3.000 2016 Ranking: 88/256 in Pharmacology & Pharmacy | 52/126 in Cardiac & Cardiovascular Systems Source: 2016 Journal Citation Reports? (Clarivate Analytics, 2017); Indexed in PubMed: MEDLINE, objectType=tool_impact_factor, channel=null, level=null, likeNumber=332, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a0e2229174, createdName=2453381967_77778861, createdTime=Thu May 31 00:00:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549434, encodeId=724c549434f3, content=以下来自官网 Journal of Cardiovascular Pharmacology and Therapeutics 2016 Impact Factor: 3.000 2016 Ranking: 88/256 in Pharmacology & Pharmacy | 52/126 in Cardiac & Cardiovascular Systems Source: 2016 Journal Citation Reports? (Clarivate Analytics, 2017); Indexed in PubMed: MEDLINE, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=366, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzXGyEIGjicRkpC7Ba3cAvgGcQ4lPPPHiagY3uGMDwl0amJesCO4IgzNdibia7ibjN2QU7JbIE3OrKxsIw/0, createdBy=a2411983122, createdName=Lijia7873, createdTime=Thu Nov 23 19:54:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549100, encodeId=ba87549100e0, content=不要版免费叶子12 2017-06-17 发表:: 研究方向：心血管; 各位朋友，您们好，我准备往这份杂志投一篇Meta分析，由于我还是一名在校研究生，没经费持续，所以想问问知道的朋友，该杂志是否免投稿的版面费呀？谢谢了，不胜感激，祝工作节节高升。发越来越多的SCI。, beContent=叶子12 2017-06-17 发表:: 研究方向：心血管; 各位朋友，您们好，我准备往这份杂志投一篇Meta分析，由于我还是一名在校研究生，没经费持续，所以想问问知道的朋友，该杂志是否免投稿的版面费呀？谢谢了，不胜感激，祝工作节节高升。发越来越多的SCI。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=324, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K6oaIJIATXp29Oic3Mpd57m5mOn1MrF2MZlGT1kqZETYTNGibicBD6OiclKRANUZyt3NJJJBb8kvU30k/0, createdBy=ccd61735665, createdName=wxsession50e170d4, createdTime=Sat Nov 11 02:11:00 CST 2017, time=2017-11-11, status=1, ipAttribution=)]

2021-12-29 Gym璨烨

我是写那种格式的摘要比较好？

82 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1092669, encodeId=de3010926697c, content=我是写那种格式的摘要比较好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092670, encodeId=030210926e030, content=摘要一般有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068169, encodeId=9c74106816911, content=偏重的研究方向：心血管;药物治疗 经验分享：请问这个杂志接受基础类研究吗？药物机制之类的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3e5463292, createdName=ms9000000616654220, createdTime=Mon Nov 08 17:13:16 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585267, encodeId=e24b58526e82, content=您好，请问您知道心血管类的网状meta分析应该投哪个杂志吗？王尛象 2018-10-25 00:00:00 发表: 10月23日晚上投的，10月25日下午被拒，理由是不再接收meta 分析类的。编辑挺友好地给回的邮件告知，做meta 的朋友就不必尝试了。, beContent=王尛象 2018-10-25 00:00:00 发表: 10月23日晚上投的，10月25日下午被拒，理由是不再接收meta 分析类的。编辑挺友好地给回的邮件告知，做meta 的朋友就不必尝试了。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=511d5270481, createdName=1482027dm93暂无昵称, createdTime=Mon Feb 24 00:00:00 CST 2020, time=2020-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579938, encodeId=17915e993842, content=请问需要版面费吗？多巴胺受体 2018-09-21 00:00:00 发表: 需要版面费吗, beContent=多巴胺受体 2018-09-21 00:00:00 发表: 需要版面费吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ba5226495, createdName=努力的科研小白, createdTime=Sat Nov 16 00:00:00 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562383, encodeId=9f4e562383a0, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：10月23日晚上投的，10月25日下午被拒，理由是不再接收meta 分析类的。编辑挺友好地给回的邮件告知，做meta 的朋友就不必尝试了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKJ73fWSxHh3xvG6CRmkSC454TlmZGCL5nXyJYuwwrvJtX7y37Q0W3jVTNKAXJvK0cZlXW85O4BdQ/132, createdBy=13532450097, createdName=王尛象, createdTime=Thu Oct 25 00:00:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561326, encodeId=ce2f56132633, content=需要版面费吗wgwang2003092 2016-08-20 22:19:00 发表: 投了一篇综述，审稿很快，审稿专家很友好！网刊更快！, beContent=wgwang2003092 2016-08-20 22:19:00 发表: 投了一篇综述，审稿很快，审稿专家很友好！网刊更快！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=287, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaELE8BUMzWSJdUBRwxgHrxk2iaPIB0NY8bDTJuSKseW0DVGuc7TAlMgB07cRxUAgPGp75ibOO3ItpezQ/132, createdBy=876d2299966, createdName=多巴胺受体, createdTime=Fri Sep 21 00:00:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=557427, encodeId=f52255e4276d, content=您好.想请教一下这个期刊的***址.找不到链接呀Lijia 2017-11-23 19:54:00 发表: 以下来自官网 Journal of Cardiovascular Pharmacology and Therapeutics 2016 Impact Factor: 3.000 2016 Ranking: 88/256 in Pharmacology & Pharmacy | 52/126 in Cardiac & Cardiovascular Systems Source: 2016 Journal Citation Reports? (Clarivate Analytics, 2017); Indexed in PubMed: MEDLINE, beContent=Lijia 2017-11-23 19:54:00 发表: 以下来自官网 Journal of Cardiovascular Pharmacology and Therapeutics 2016 Impact Factor: 3.000 2016 Ranking: 88/256 in Pharmacology & Pharmacy | 52/126 in Cardiac & Cardiovascular Systems Source: 2016 Journal Citation Reports? (Clarivate Analytics, 2017); Indexed in PubMed: MEDLINE, objectType=tool_impact_factor, channel=null, level=null, likeNumber=332, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a0e2229174, createdName=2453381967_77778861, createdTime=Thu May 31 00:00:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549434, encodeId=724c549434f3, content=以下来自官网 Journal of Cardiovascular Pharmacology and Therapeutics 2016 Impact Factor: 3.000 2016 Ranking: 88/256 in Pharmacology & Pharmacy | 52/126 in Cardiac & Cardiovascular Systems Source: 2016 Journal Citation Reports? (Clarivate Analytics, 2017); Indexed in PubMed: MEDLINE, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=366, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzXGyEIGjicRkpC7Ba3cAvgGcQ4lPPPHiagY3uGMDwl0amJesCO4IgzNdibia7ibjN2QU7JbIE3OrKxsIw/0, createdBy=a2411983122, createdName=Lijia7873, createdTime=Thu Nov 23 19:54:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549100, encodeId=ba87549100e0, content=不要版免费叶子12 2017-06-17 发表:: 研究方向：心血管; 各位朋友，您们好，我准备往这份杂志投一篇Meta分析，由于我还是一名在校研究生，没经费持续，所以想问问知道的朋友，该杂志是否免投稿的版面费呀？谢谢了，不胜感激，祝工作节节高升。发越来越多的SCI。, beContent=叶子12 2017-06-17 发表:: 研究方向：心血管; 各位朋友，您们好，我准备往这份杂志投一篇Meta分析，由于我还是一名在校研究生，没经费持续，所以想问问知道的朋友，该杂志是否免投稿的版面费呀？谢谢了，不胜感激，祝工作节节高升。发越来越多的SCI。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=324, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K6oaIJIATXp29Oic3Mpd57m5mOn1MrF2MZlGT1kqZETYTNGibicBD6OiclKRANUZyt3NJJJBb8kvU30k/0, createdBy=ccd61735665, createdName=wxsession50e170d4, createdTime=Sat Nov 11 02:11:00 CST 2017, time=2017-11-11, status=1, ipAttribution=)]

2021-12-28 Gym璨烨

摘要一般有什么要求？

77 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1092669, encodeId=de3010926697c, content=我是写那种格式的摘要比较好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092670, encodeId=030210926e030, content=摘要一般有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068169, encodeId=9c74106816911, content=偏重的研究方向：心血管;药物治疗 经验分享：请问这个杂志接受基础类研究吗？药物机制之类的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3e5463292, createdName=ms9000000616654220, createdTime=Mon Nov 08 17:13:16 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585267, encodeId=e24b58526e82, content=您好，请问您知道心血管类的网状meta分析应该投哪个杂志吗？王尛象 2018-10-25 00:00:00 发表: 10月23日晚上投的，10月25日下午被拒，理由是不再接收meta 分析类的。编辑挺友好地给回的邮件告知，做meta 的朋友就不必尝试了。, beContent=王尛象 2018-10-25 00:00:00 发表: 10月23日晚上投的，10月25日下午被拒，理由是不再接收meta 分析类的。编辑挺友好地给回的邮件告知，做meta 的朋友就不必尝试了。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=511d5270481, createdName=1482027dm93暂无昵称, createdTime=Mon Feb 24 00:00:00 CST 2020, time=2020-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579938, encodeId=17915e993842, content=请问需要版面费吗？多巴胺受体 2018-09-21 00:00:00 发表: 需要版面费吗, beContent=多巴胺受体 2018-09-21 00:00:00 发表: 需要版面费吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ba5226495, createdName=努力的科研小白, createdTime=Sat Nov 16 00:00:00 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562383, encodeId=9f4e562383a0, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：10月23日晚上投的，10月25日下午被拒，理由是不再接收meta 分析类的。编辑挺友好地给回的邮件告知，做meta 的朋友就不必尝试了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKJ73fWSxHh3xvG6CRmkSC454TlmZGCL5nXyJYuwwrvJtX7y37Q0W3jVTNKAXJvK0cZlXW85O4BdQ/132, createdBy=13532450097, createdName=王尛象, createdTime=Thu Oct 25 00:00:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561326, encodeId=ce2f56132633, content=需要版面费吗wgwang2003092 2016-08-20 22:19:00 发表: 投了一篇综述，审稿很快，审稿专家很友好！网刊更快！, beContent=wgwang2003092 2016-08-20 22:19:00 发表: 投了一篇综述，审稿很快，审稿专家很友好！网刊更快！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=287, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaELE8BUMzWSJdUBRwxgHrxk2iaPIB0NY8bDTJuSKseW0DVGuc7TAlMgB07cRxUAgPGp75ibOO3ItpezQ/132, createdBy=876d2299966, createdName=多巴胺受体, createdTime=Fri Sep 21 00:00:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=557427, encodeId=f52255e4276d, content=您好.想请教一下这个期刊的***址.找不到链接呀Lijia 2017-11-23 19:54:00 发表: 以下来自官网 Journal of Cardiovascular Pharmacology and Therapeutics 2016 Impact Factor: 3.000 2016 Ranking: 88/256 in Pharmacology & Pharmacy | 52/126 in Cardiac & Cardiovascular Systems Source: 2016 Journal Citation Reports? (Clarivate Analytics, 2017); Indexed in PubMed: MEDLINE, beContent=Lijia 2017-11-23 19:54:00 发表: 以下来自官网 Journal of Cardiovascular Pharmacology and Therapeutics 2016 Impact Factor: 3.000 2016 Ranking: 88/256 in Pharmacology & Pharmacy | 52/126 in Cardiac & Cardiovascular Systems Source: 2016 Journal Citation Reports? (Clarivate Analytics, 2017); Indexed in PubMed: MEDLINE, objectType=tool_impact_factor, channel=null, level=null, likeNumber=332, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a0e2229174, createdName=2453381967_77778861, createdTime=Thu May 31 00:00:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549434, encodeId=724c549434f3, content=以下来自官网 Journal of Cardiovascular Pharmacology and Therapeutics 2016 Impact Factor: 3.000 2016 Ranking: 88/256 in Pharmacology & Pharmacy | 52/126 in Cardiac & Cardiovascular Systems Source: 2016 Journal Citation Reports? (Clarivate Analytics, 2017); Indexed in PubMed: MEDLINE, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=366, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzXGyEIGjicRkpC7Ba3cAvgGcQ4lPPPHiagY3uGMDwl0amJesCO4IgzNdibia7ibjN2QU7JbIE3OrKxsIw/0, createdBy=a2411983122, createdName=Lijia7873, createdTime=Thu Nov 23 19:54:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549100, encodeId=ba87549100e0, content=不要版免费叶子12 2017-06-17 发表:: 研究方向：心血管; 各位朋友，您们好，我准备往这份杂志投一篇Meta分析，由于我还是一名在校研究生，没经费持续，所以想问问知道的朋友，该杂志是否免投稿的版面费呀？谢谢了，不胜感激，祝工作节节高升。发越来越多的SCI。, beContent=叶子12 2017-06-17 发表:: 研究方向：心血管; 各位朋友，您们好，我准备往这份杂志投一篇Meta分析，由于我还是一名在校研究生，没经费持续，所以想问问知道的朋友，该杂志是否免投稿的版面费呀？谢谢了，不胜感激，祝工作节节高升。发越来越多的SCI。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=324, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K6oaIJIATXp29Oic3Mpd57m5mOn1MrF2MZlGT1kqZETYTNGibicBD6OiclKRANUZyt3NJJJBb8kvU30k/0, createdBy=ccd61735665, createdName=wxsession50e170d4, createdTime=Sat Nov 11 02:11:00 CST 2017, time=2017-11-11, status=1, ipAttribution=)]

2021-11-08 ms9000000616654220

偏重的研究方向：心血管;药物治疗
经验分享：请问这个杂志接受基础类研究吗？药物机制之类的？

92 0

[GetPortalCommentsPageByObjectIdResponse(id=1092669, encodeId=de3010926697c, content=我是写那种格式的摘要比较好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092670, encodeId=030210926e030, content=摘要一般有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068169, encodeId=9c74106816911, content=偏重的研究方向：心血管;药物治疗 经验分享：请问这个杂志接受基础类研究吗？药物机制之类的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3e5463292, createdName=ms9000000616654220, createdTime=Mon Nov 08 17:13:16 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585267, encodeId=e24b58526e82, content=您好，请问您知道心血管类的网状meta分析应该投哪个杂志吗？王尛象 2018-10-25 00:00:00 发表: 10月23日晚上投的，10月25日下午被拒，理由是不再接收meta 分析类的。编辑挺友好地给回的邮件告知，做meta 的朋友就不必尝试了。, beContent=王尛象 2018-10-25 00:00:00 发表: 10月23日晚上投的，10月25日下午被拒，理由是不再接收meta 分析类的。编辑挺友好地给回的邮件告知，做meta 的朋友就不必尝试了。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=511d5270481, createdName=1482027dm93暂无昵称, createdTime=Mon Feb 24 00:00:00 CST 2020, time=2020-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579938, encodeId=17915e993842, content=请问需要版面费吗？多巴胺受体 2018-09-21 00:00:00 发表: 需要版面费吗, beContent=多巴胺受体 2018-09-21 00:00:00 发表: 需要版面费吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ba5226495, createdName=努力的科研小白, createdTime=Sat Nov 16 00:00:00 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562383, encodeId=9f4e562383a0, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：10月23日晚上投的，10月25日下午被拒，理由是不再接收meta 分析类的。编辑挺友好地给回的邮件告知，做meta 的朋友就不必尝试了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKJ73fWSxHh3xvG6CRmkSC454TlmZGCL5nXyJYuwwrvJtX7y37Q0W3jVTNKAXJvK0cZlXW85O4BdQ/132, createdBy=13532450097, createdName=王尛象, createdTime=Thu Oct 25 00:00:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561326, encodeId=ce2f56132633, content=需要版面费吗wgwang2003092 2016-08-20 22:19:00 发表: 投了一篇综述，审稿很快，审稿专家很友好！网刊更快！, beContent=wgwang2003092 2016-08-20 22:19:00 发表: 投了一篇综述，审稿很快，审稿专家很友好！网刊更快！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=287, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaELE8BUMzWSJdUBRwxgHrxk2iaPIB0NY8bDTJuSKseW0DVGuc7TAlMgB07cRxUAgPGp75ibOO3ItpezQ/132, createdBy=876d2299966, createdName=多巴胺受体, createdTime=Fri Sep 21 00:00:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=557427, encodeId=f52255e4276d, content=您好.想请教一下这个期刊的***址.找不到链接呀Lijia 2017-11-23 19:54:00 发表: 以下来自官网 Journal of Cardiovascular Pharmacology and Therapeutics 2016 Impact Factor: 3.000 2016 Ranking: 88/256 in Pharmacology & Pharmacy | 52/126 in Cardiac & Cardiovascular Systems Source: 2016 Journal Citation Reports? (Clarivate Analytics, 2017); Indexed in PubMed: MEDLINE, beContent=Lijia 2017-11-23 19:54:00 发表: 以下来自官网 Journal of Cardiovascular Pharmacology and Therapeutics 2016 Impact Factor: 3.000 2016 Ranking: 88/256 in Pharmacology & Pharmacy | 52/126 in Cardiac & Cardiovascular Systems Source: 2016 Journal Citation Reports? (Clarivate Analytics, 2017); Indexed in PubMed: MEDLINE, objectType=tool_impact_factor, channel=null, level=null, likeNumber=332, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a0e2229174, createdName=2453381967_77778861, createdTime=Thu May 31 00:00:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549434, encodeId=724c549434f3, content=以下来自官网 Journal of Cardiovascular Pharmacology and Therapeutics 2016 Impact Factor: 3.000 2016 Ranking: 88/256 in Pharmacology & Pharmacy | 52/126 in Cardiac & Cardiovascular Systems Source: 2016 Journal Citation Reports? (Clarivate Analytics, 2017); Indexed in PubMed: MEDLINE, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=366, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzXGyEIGjicRkpC7Ba3cAvgGcQ4lPPPHiagY3uGMDwl0amJesCO4IgzNdibia7ibjN2QU7JbIE3OrKxsIw/0, createdBy=a2411983122, createdName=Lijia7873, createdTime=Thu Nov 23 19:54:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549100, encodeId=ba87549100e0, content=不要版免费叶子12 2017-06-17 发表:: 研究方向：心血管; 各位朋友，您们好，我准备往这份杂志投一篇Meta分析，由于我还是一名在校研究生，没经费持续，所以想问问知道的朋友，该杂志是否免投稿的版面费呀？谢谢了，不胜感激，祝工作节节高升。发越来越多的SCI。, beContent=叶子12 2017-06-17 发表:: 研究方向：心血管; 各位朋友，您们好，我准备往这份杂志投一篇Meta分析，由于我还是一名在校研究生，没经费持续，所以想问问知道的朋友，该杂志是否免投稿的版面费呀？谢谢了，不胜感激，祝工作节节高升。发越来越多的SCI。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=324, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K6oaIJIATXp29Oic3Mpd57m5mOn1MrF2MZlGT1kqZETYTNGibicBD6OiclKRANUZyt3NJJJBb8kvU30k/0, createdBy=ccd61735665, createdName=wxsession50e170d4, createdTime=Sat Nov 11 02:11:00 CST 2017, time=2017-11-11, status=1, ipAttribution=)]

2020-02-24 1482027dm93暂无昵称

您好，请问您知道心血管类的网状meta分析应该投哪个杂志吗？王尛象 2018-10-25 00:00:00 发表:
10月23日晚上投的，10月25日下午被拒，理由是不再接收meta 分析类的。编辑挺友好地给回的邮件告知，做meta 的朋友就不必尝试了。

王尛象 2018-10-25 00:00:00 发表: 10月23日晚上投的，10月25日下午被拒，理由是不再接收meta 分析类的。编辑挺友好地给回的邮件告知，做meta 的朋友就不必尝试了。

168 0

[GetPortalCommentsPageByObjectIdResponse(id=1092669, encodeId=de3010926697c, content=我是写那种格式的摘要比较好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092670, encodeId=030210926e030, content=摘要一般有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068169, encodeId=9c74106816911, content=偏重的研究方向：心血管;药物治疗 经验分享：请问这个杂志接受基础类研究吗？药物机制之类的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3e5463292, createdName=ms9000000616654220, createdTime=Mon Nov 08 17:13:16 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585267, encodeId=e24b58526e82, content=您好，请问您知道心血管类的网状meta分析应该投哪个杂志吗？王尛象 2018-10-25 00:00:00 发表: 10月23日晚上投的，10月25日下午被拒，理由是不再接收meta 分析类的。编辑挺友好地给回的邮件告知，做meta 的朋友就不必尝试了。, beContent=王尛象 2018-10-25 00:00:00 发表: 10月23日晚上投的，10月25日下午被拒，理由是不再接收meta 分析类的。编辑挺友好地给回的邮件告知，做meta 的朋友就不必尝试了。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=511d5270481, createdName=1482027dm93暂无昵称, createdTime=Mon Feb 24 00:00:00 CST 2020, time=2020-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579938, encodeId=17915e993842, content=请问需要版面费吗？多巴胺受体 2018-09-21 00:00:00 发表: 需要版面费吗, beContent=多巴胺受体 2018-09-21 00:00:00 发表: 需要版面费吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ba5226495, createdName=努力的科研小白, createdTime=Sat Nov 16 00:00:00 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562383, encodeId=9f4e562383a0, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：10月23日晚上投的，10月25日下午被拒，理由是不再接收meta 分析类的。编辑挺友好地给回的邮件告知，做meta 的朋友就不必尝试了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKJ73fWSxHh3xvG6CRmkSC454TlmZGCL5nXyJYuwwrvJtX7y37Q0W3jVTNKAXJvK0cZlXW85O4BdQ/132, createdBy=13532450097, createdName=王尛象, createdTime=Thu Oct 25 00:00:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561326, encodeId=ce2f56132633, content=需要版面费吗wgwang2003092 2016-08-20 22:19:00 发表: 投了一篇综述，审稿很快，审稿专家很友好！网刊更快！, beContent=wgwang2003092 2016-08-20 22:19:00 发表: 投了一篇综述，审稿很快，审稿专家很友好！网刊更快！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=287, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaELE8BUMzWSJdUBRwxgHrxk2iaPIB0NY8bDTJuSKseW0DVGuc7TAlMgB07cRxUAgPGp75ibOO3ItpezQ/132, createdBy=876d2299966, createdName=多巴胺受体, createdTime=Fri Sep 21 00:00:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=557427, encodeId=f52255e4276d, content=您好.想请教一下这个期刊的***址.找不到链接呀Lijia 2017-11-23 19:54:00 发表: 以下来自官网 Journal of Cardiovascular Pharmacology and Therapeutics 2016 Impact Factor: 3.000 2016 Ranking: 88/256 in Pharmacology & Pharmacy | 52/126 in Cardiac & Cardiovascular Systems Source: 2016 Journal Citation Reports? (Clarivate Analytics, 2017); Indexed in PubMed: MEDLINE, beContent=Lijia 2017-11-23 19:54:00 发表: 以下来自官网 Journal of Cardiovascular Pharmacology and Therapeutics 2016 Impact Factor: 3.000 2016 Ranking: 88/256 in Pharmacology & Pharmacy | 52/126 in Cardiac & Cardiovascular Systems Source: 2016 Journal Citation Reports? (Clarivate Analytics, 2017); Indexed in PubMed: MEDLINE, objectType=tool_impact_factor, channel=null, level=null, likeNumber=332, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a0e2229174, createdName=2453381967_77778861, createdTime=Thu May 31 00:00:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549434, encodeId=724c549434f3, content=以下来自官网 Journal of Cardiovascular Pharmacology and Therapeutics 2016 Impact Factor: 3.000 2016 Ranking: 88/256 in Pharmacology & Pharmacy | 52/126 in Cardiac & Cardiovascular Systems Source: 2016 Journal Citation Reports? (Clarivate Analytics, 2017); Indexed in PubMed: MEDLINE, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=366, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzXGyEIGjicRkpC7Ba3cAvgGcQ4lPPPHiagY3uGMDwl0amJesCO4IgzNdibia7ibjN2QU7JbIE3OrKxsIw/0, createdBy=a2411983122, createdName=Lijia7873, createdTime=Thu Nov 23 19:54:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549100, encodeId=ba87549100e0, content=不要版免费叶子12 2017-06-17 发表:: 研究方向：心血管; 各位朋友，您们好，我准备往这份杂志投一篇Meta分析，由于我还是一名在校研究生，没经费持续，所以想问问知道的朋友，该杂志是否免投稿的版面费呀？谢谢了，不胜感激，祝工作节节高升。发越来越多的SCI。, beContent=叶子12 2017-06-17 发表:: 研究方向：心血管; 各位朋友，您们好，我准备往这份杂志投一篇Meta分析，由于我还是一名在校研究生，没经费持续，所以想问问知道的朋友，该杂志是否免投稿的版面费呀？谢谢了，不胜感激，祝工作节节高升。发越来越多的SCI。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=324, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K6oaIJIATXp29Oic3Mpd57m5mOn1MrF2MZlGT1kqZETYTNGibicBD6OiclKRANUZyt3NJJJBb8kvU30k/0, createdBy=ccd61735665, createdName=wxsession50e170d4, createdTime=Sat Nov 11 02:11:00 CST 2017, time=2017-11-11, status=1, ipAttribution=)]

2019-11-16 努力的科研小白

请问需要版面费吗？多巴胺受体 2018-09-21 00:00:00 发表:
需要版面费吗

多巴胺受体 2018-09-21 00:00:00 发表: 需要版面费吗

192 0

[GetPortalCommentsPageByObjectIdResponse(id=1092669, encodeId=de3010926697c, content=我是写那种格式的摘要比较好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092670, encodeId=030210926e030, content=摘要一般有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068169, encodeId=9c74106816911, content=偏重的研究方向：心血管;药物治疗 经验分享：请问这个杂志接受基础类研究吗？药物机制之类的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3e5463292, createdName=ms9000000616654220, createdTime=Mon Nov 08 17:13:16 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585267, encodeId=e24b58526e82, content=您好，请问您知道心血管类的网状meta分析应该投哪个杂志吗？王尛象 2018-10-25 00:00:00 发表: 10月23日晚上投的，10月25日下午被拒，理由是不再接收meta 分析类的。编辑挺友好地给回的邮件告知，做meta 的朋友就不必尝试了。, beContent=王尛象 2018-10-25 00:00:00 发表: 10月23日晚上投的，10月25日下午被拒，理由是不再接收meta 分析类的。编辑挺友好地给回的邮件告知，做meta 的朋友就不必尝试了。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=511d5270481, createdName=1482027dm93暂无昵称, createdTime=Mon Feb 24 00:00:00 CST 2020, time=2020-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579938, encodeId=17915e993842, content=请问需要版面费吗？多巴胺受体 2018-09-21 00:00:00 发表: 需要版面费吗, beContent=多巴胺受体 2018-09-21 00:00:00 发表: 需要版面费吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ba5226495, createdName=努力的科研小白, createdTime=Sat Nov 16 00:00:00 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562383, encodeId=9f4e562383a0, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：10月23日晚上投的，10月25日下午被拒，理由是不再接收meta 分析类的。编辑挺友好地给回的邮件告知，做meta 的朋友就不必尝试了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKJ73fWSxHh3xvG6CRmkSC454TlmZGCL5nXyJYuwwrvJtX7y37Q0W3jVTNKAXJvK0cZlXW85O4BdQ/132, createdBy=13532450097, createdName=王尛象, createdTime=Thu Oct 25 00:00:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561326, encodeId=ce2f56132633, content=需要版面费吗wgwang2003092 2016-08-20 22:19:00 发表: 投了一篇综述，审稿很快，审稿专家很友好！网刊更快！, beContent=wgwang2003092 2016-08-20 22:19:00 发表: 投了一篇综述，审稿很快，审稿专家很友好！网刊更快！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=287, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaELE8BUMzWSJdUBRwxgHrxk2iaPIB0NY8bDTJuSKseW0DVGuc7TAlMgB07cRxUAgPGp75ibOO3ItpezQ/132, createdBy=876d2299966, createdName=多巴胺受体, createdTime=Fri Sep 21 00:00:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=557427, encodeId=f52255e4276d, content=您好.想请教一下这个期刊的***址.找不到链接呀Lijia 2017-11-23 19:54:00 发表: 以下来自官网 Journal of Cardiovascular Pharmacology and Therapeutics 2016 Impact Factor: 3.000 2016 Ranking: 88/256 in Pharmacology & Pharmacy | 52/126 in Cardiac & Cardiovascular Systems Source: 2016 Journal Citation Reports? (Clarivate Analytics, 2017); Indexed in PubMed: MEDLINE, beContent=Lijia 2017-11-23 19:54:00 发表: 以下来自官网 Journal of Cardiovascular Pharmacology and Therapeutics 2016 Impact Factor: 3.000 2016 Ranking: 88/256 in Pharmacology & Pharmacy | 52/126 in Cardiac & Cardiovascular Systems Source: 2016 Journal Citation Reports? (Clarivate Analytics, 2017); Indexed in PubMed: MEDLINE, objectType=tool_impact_factor, channel=null, level=null, likeNumber=332, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a0e2229174, createdName=2453381967_77778861, createdTime=Thu May 31 00:00:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549434, encodeId=724c549434f3, content=以下来自官网 Journal of Cardiovascular Pharmacology and Therapeutics 2016 Impact Factor: 3.000 2016 Ranking: 88/256 in Pharmacology & Pharmacy | 52/126 in Cardiac & Cardiovascular Systems Source: 2016 Journal Citation Reports? (Clarivate Analytics, 2017); Indexed in PubMed: MEDLINE, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=366, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzXGyEIGjicRkpC7Ba3cAvgGcQ4lPPPHiagY3uGMDwl0amJesCO4IgzNdibia7ibjN2QU7JbIE3OrKxsIw/0, createdBy=a2411983122, createdName=Lijia7873, createdTime=Thu Nov 23 19:54:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549100, encodeId=ba87549100e0, content=不要版免费叶子12 2017-06-17 发表:: 研究方向：心血管; 各位朋友，您们好，我准备往这份杂志投一篇Meta分析，由于我还是一名在校研究生，没经费持续，所以想问问知道的朋友，该杂志是否免投稿的版面费呀？谢谢了，不胜感激，祝工作节节高升。发越来越多的SCI。, beContent=叶子12 2017-06-17 发表:: 研究方向：心血管; 各位朋友，您们好，我准备往这份杂志投一篇Meta分析，由于我还是一名在校研究生，没经费持续，所以想问问知道的朋友，该杂志是否免投稿的版面费呀？谢谢了，不胜感激，祝工作节节高升。发越来越多的SCI。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=324, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K6oaIJIATXp29Oic3Mpd57m5mOn1MrF2MZlGT1kqZETYTNGibicBD6OiclKRANUZyt3NJJJBb8kvU30k/0, createdBy=ccd61735665, createdName=wxsession50e170d4, createdTime=Sat Nov 11 02:11:00 CST 2017, time=2017-11-11, status=1, ipAttribution=)]

2018-10-25 王尛象

审稿速度:1.0 | 投稿命中率:25.0
经验分享：10月23日晚上投的，10月25日下午被拒，理由是不再接收meta 分析类的。编辑挺友好地给回的邮件告知，做meta 的朋友就不必尝试了。

302 0

[GetPortalCommentsPageByObjectIdResponse(id=1092669, encodeId=de3010926697c, content=我是写那种格式的摘要比较好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092670, encodeId=030210926e030, content=摘要一般有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068169, encodeId=9c74106816911, content=偏重的研究方向：心血管;药物治疗 经验分享：请问这个杂志接受基础类研究吗？药物机制之类的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3e5463292, createdName=ms9000000616654220, createdTime=Mon Nov 08 17:13:16 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585267, encodeId=e24b58526e82, content=您好，请问您知道心血管类的网状meta分析应该投哪个杂志吗？王尛象 2018-10-25 00:00:00 发表: 10月23日晚上投的，10月25日下午被拒，理由是不再接收meta 分析类的。编辑挺友好地给回的邮件告知，做meta 的朋友就不必尝试了。, beContent=王尛象 2018-10-25 00:00:00 发表: 10月23日晚上投的，10月25日下午被拒，理由是不再接收meta 分析类的。编辑挺友好地给回的邮件告知，做meta 的朋友就不必尝试了。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=511d5270481, createdName=1482027dm93暂无昵称, createdTime=Mon Feb 24 00:00:00 CST 2020, time=2020-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579938, encodeId=17915e993842, content=请问需要版面费吗？多巴胺受体 2018-09-21 00:00:00 发表: 需要版面费吗, beContent=多巴胺受体 2018-09-21 00:00:00 发表: 需要版面费吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ba5226495, createdName=努力的科研小白, createdTime=Sat Nov 16 00:00:00 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562383, encodeId=9f4e562383a0, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：10月23日晚上投的，10月25日下午被拒，理由是不再接收meta 分析类的。编辑挺友好地给回的邮件告知，做meta 的朋友就不必尝试了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKJ73fWSxHh3xvG6CRmkSC454TlmZGCL5nXyJYuwwrvJtX7y37Q0W3jVTNKAXJvK0cZlXW85O4BdQ/132, createdBy=13532450097, createdName=王尛象, createdTime=Thu Oct 25 00:00:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561326, encodeId=ce2f56132633, content=需要版面费吗wgwang2003092 2016-08-20 22:19:00 发表: 投了一篇综述，审稿很快，审稿专家很友好！网刊更快！, beContent=wgwang2003092 2016-08-20 22:19:00 发表: 投了一篇综述，审稿很快，审稿专家很友好！网刊更快！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=287, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaELE8BUMzWSJdUBRwxgHrxk2iaPIB0NY8bDTJuSKseW0DVGuc7TAlMgB07cRxUAgPGp75ibOO3ItpezQ/132, createdBy=876d2299966, createdName=多巴胺受体, createdTime=Fri Sep 21 00:00:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=557427, encodeId=f52255e4276d, content=您好.想请教一下这个期刊的***址.找不到链接呀Lijia 2017-11-23 19:54:00 发表: 以下来自官网 Journal of Cardiovascular Pharmacology and Therapeutics 2016 Impact Factor: 3.000 2016 Ranking: 88/256 in Pharmacology & Pharmacy | 52/126 in Cardiac & Cardiovascular Systems Source: 2016 Journal Citation Reports? (Clarivate Analytics, 2017); Indexed in PubMed: MEDLINE, beContent=Lijia 2017-11-23 19:54:00 发表: 以下来自官网 Journal of Cardiovascular Pharmacology and Therapeutics 2016 Impact Factor: 3.000 2016 Ranking: 88/256 in Pharmacology & Pharmacy | 52/126 in Cardiac & Cardiovascular Systems Source: 2016 Journal Citation Reports? (Clarivate Analytics, 2017); Indexed in PubMed: MEDLINE, objectType=tool_impact_factor, channel=null, level=null, likeNumber=332, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a0e2229174, createdName=2453381967_77778861, createdTime=Thu May 31 00:00:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549434, encodeId=724c549434f3, content=以下来自官网 Journal of Cardiovascular Pharmacology and Therapeutics 2016 Impact Factor: 3.000 2016 Ranking: 88/256 in Pharmacology & Pharmacy | 52/126 in Cardiac & Cardiovascular Systems Source: 2016 Journal Citation Reports? (Clarivate Analytics, 2017); Indexed in PubMed: MEDLINE, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=366, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzXGyEIGjicRkpC7Ba3cAvgGcQ4lPPPHiagY3uGMDwl0amJesCO4IgzNdibia7ibjN2QU7JbIE3OrKxsIw/0, createdBy=a2411983122, createdName=Lijia7873, createdTime=Thu Nov 23 19:54:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549100, encodeId=ba87549100e0, content=不要版免费叶子12 2017-06-17 发表:: 研究方向：心血管; 各位朋友，您们好，我准备往这份杂志投一篇Meta分析，由于我还是一名在校研究生，没经费持续，所以想问问知道的朋友，该杂志是否免投稿的版面费呀？谢谢了，不胜感激，祝工作节节高升。发越来越多的SCI。, beContent=叶子12 2017-06-17 发表:: 研究方向：心血管; 各位朋友，您们好，我准备往这份杂志投一篇Meta分析，由于我还是一名在校研究生，没经费持续，所以想问问知道的朋友，该杂志是否免投稿的版面费呀？谢谢了，不胜感激，祝工作节节高升。发越来越多的SCI。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=324, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K6oaIJIATXp29Oic3Mpd57m5mOn1MrF2MZlGT1kqZETYTNGibicBD6OiclKRANUZyt3NJJJBb8kvU30k/0, createdBy=ccd61735665, createdName=wxsession50e170d4, createdTime=Sat Nov 11 02:11:00 CST 2017, time=2017-11-11, status=1, ipAttribution=)]

2018-09-21 多巴胺受体

需要版面费吗wgwang2003092 2016-08-20 22:19:00 发表:
投了一篇综述，审稿很快，审稿专家很友好！网刊更快！

wgwang2003092 2016-08-20 22:19:00 发表: 投了一篇综述，审稿很快，审稿专家很友好！网刊更快！

287 0

[GetPortalCommentsPageByObjectIdResponse(id=1092669, encodeId=de3010926697c, content=我是写那种格式的摘要比较好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092670, encodeId=030210926e030, content=摘要一般有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068169, encodeId=9c74106816911, content=偏重的研究方向：心血管;药物治疗 经验分享：请问这个杂志接受基础类研究吗？药物机制之类的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3e5463292, createdName=ms9000000616654220, createdTime=Mon Nov 08 17:13:16 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585267, encodeId=e24b58526e82, content=您好，请问您知道心血管类的网状meta分析应该投哪个杂志吗？王尛象 2018-10-25 00:00:00 发表: 10月23日晚上投的，10月25日下午被拒，理由是不再接收meta 分析类的。编辑挺友好地给回的邮件告知，做meta 的朋友就不必尝试了。, beContent=王尛象 2018-10-25 00:00:00 发表: 10月23日晚上投的，10月25日下午被拒，理由是不再接收meta 分析类的。编辑挺友好地给回的邮件告知，做meta 的朋友就不必尝试了。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=511d5270481, createdName=1482027dm93暂无昵称, createdTime=Mon Feb 24 00:00:00 CST 2020, time=2020-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579938, encodeId=17915e993842, content=请问需要版面费吗？多巴胺受体 2018-09-21 00:00:00 发表: 需要版面费吗, beContent=多巴胺受体 2018-09-21 00:00:00 发表: 需要版面费吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ba5226495, createdName=努力的科研小白, createdTime=Sat Nov 16 00:00:00 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562383, encodeId=9f4e562383a0, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：10月23日晚上投的，10月25日下午被拒，理由是不再接收meta 分析类的。编辑挺友好地给回的邮件告知，做meta 的朋友就不必尝试了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKJ73fWSxHh3xvG6CRmkSC454TlmZGCL5nXyJYuwwrvJtX7y37Q0W3jVTNKAXJvK0cZlXW85O4BdQ/132, createdBy=13532450097, createdName=王尛象, createdTime=Thu Oct 25 00:00:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561326, encodeId=ce2f56132633, content=需要版面费吗wgwang2003092 2016-08-20 22:19:00 发表: 投了一篇综述，审稿很快，审稿专家很友好！网刊更快！, beContent=wgwang2003092 2016-08-20 22:19:00 发表: 投了一篇综述，审稿很快，审稿专家很友好！网刊更快！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=287, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaELE8BUMzWSJdUBRwxgHrxk2iaPIB0NY8bDTJuSKseW0DVGuc7TAlMgB07cRxUAgPGp75ibOO3ItpezQ/132, createdBy=876d2299966, createdName=多巴胺受体, createdTime=Fri Sep 21 00:00:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=557427, encodeId=f52255e4276d, content=您好.想请教一下这个期刊的***址.找不到链接呀Lijia 2017-11-23 19:54:00 发表: 以下来自官网 Journal of Cardiovascular Pharmacology and Therapeutics 2016 Impact Factor: 3.000 2016 Ranking: 88/256 in Pharmacology & Pharmacy | 52/126 in Cardiac & Cardiovascular Systems Source: 2016 Journal Citation Reports? (Clarivate Analytics, 2017); Indexed in PubMed: MEDLINE, beContent=Lijia 2017-11-23 19:54:00 发表: 以下来自官网 Journal of Cardiovascular Pharmacology and Therapeutics 2016 Impact Factor: 3.000 2016 Ranking: 88/256 in Pharmacology & Pharmacy | 52/126 in Cardiac & Cardiovascular Systems Source: 2016 Journal Citation Reports? (Clarivate Analytics, 2017); Indexed in PubMed: MEDLINE, objectType=tool_impact_factor, channel=null, level=null, likeNumber=332, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a0e2229174, createdName=2453381967_77778861, createdTime=Thu May 31 00:00:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549434, encodeId=724c549434f3, content=以下来自官网 Journal of Cardiovascular Pharmacology and Therapeutics 2016 Impact Factor: 3.000 2016 Ranking: 88/256 in Pharmacology & Pharmacy | 52/126 in Cardiac & Cardiovascular Systems Source: 2016 Journal Citation Reports? (Clarivate Analytics, 2017); Indexed in PubMed: MEDLINE, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=366, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzXGyEIGjicRkpC7Ba3cAvgGcQ4lPPPHiagY3uGMDwl0amJesCO4IgzNdibia7ibjN2QU7JbIE3OrKxsIw/0, createdBy=a2411983122, createdName=Lijia7873, createdTime=Thu Nov 23 19:54:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549100, encodeId=ba87549100e0, content=不要版免费叶子12 2017-06-17 发表:: 研究方向：心血管; 各位朋友，您们好，我准备往这份杂志投一篇Meta分析，由于我还是一名在校研究生，没经费持续，所以想问问知道的朋友，该杂志是否免投稿的版面费呀？谢谢了，不胜感激，祝工作节节高升。发越来越多的SCI。, beContent=叶子12 2017-06-17 发表:: 研究方向：心血管; 各位朋友，您们好，我准备往这份杂志投一篇Meta分析，由于我还是一名在校研究生，没经费持续，所以想问问知道的朋友，该杂志是否免投稿的版面费呀？谢谢了，不胜感激，祝工作节节高升。发越来越多的SCI。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=324, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K6oaIJIATXp29Oic3Mpd57m5mOn1MrF2MZlGT1kqZETYTNGibicBD6OiclKRANUZyt3NJJJBb8kvU30k/0, createdBy=ccd61735665, createdName=wxsession50e170d4, createdTime=Sat Nov 11 02:11:00 CST 2017, time=2017-11-11, status=1, ipAttribution=)]

2018-05-31 2453381967_77778861

您好.想请教一下这个期刊的***址.找不到链接呀Lijia 2017-11-23 19:54:00 发表:
以下来自官网
Journal of Cardiovascular Pharmacology and Therapeutics
2016 Impact Factor: 3.000
2016 Ranking: 88/256 in Pharmacology & Pharmacy | 52/126 in Cardiac & Cardiovascular Systems
Source: 2016 Journal Citation Reports? (Clarivate Analytics, 2017); Indexed in PubMed: MEDLINE

Lijia 2017-11-23 19:54:00 发表: 以下来自官网
Journal of Cardiovascular Pharmacology and Therapeutics
2016 Impact Factor: 3.000
2016 Ranking: 88/256 in Pharmacology & Pharmacy | 52/126 in Cardiac & Cardiovascular Systems
Source: 2016 Journal Citation Reports? (Clarivate Analytics, 2017); Indexed in PubMed: MEDLINE

332 0

[GetPortalCommentsPageByObjectIdResponse(id=1092669, encodeId=de3010926697c, content=我是写那种格式的摘要比较好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092670, encodeId=030210926e030, content=摘要一般有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068169, encodeId=9c74106816911, content=偏重的研究方向：心血管;药物治疗 经验分享：请问这个杂志接受基础类研究吗？药物机制之类的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3e5463292, createdName=ms9000000616654220, createdTime=Mon Nov 08 17:13:16 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585267, encodeId=e24b58526e82, content=您好，请问您知道心血管类的网状meta分析应该投哪个杂志吗？王尛象 2018-10-25 00:00:00 发表: 10月23日晚上投的，10月25日下午被拒，理由是不再接收meta 分析类的。编辑挺友好地给回的邮件告知，做meta 的朋友就不必尝试了。, beContent=王尛象 2018-10-25 00:00:00 发表: 10月23日晚上投的，10月25日下午被拒，理由是不再接收meta 分析类的。编辑挺友好地给回的邮件告知，做meta 的朋友就不必尝试了。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=511d5270481, createdName=1482027dm93暂无昵称, createdTime=Mon Feb 24 00:00:00 CST 2020, time=2020-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579938, encodeId=17915e993842, content=请问需要版面费吗？多巴胺受体 2018-09-21 00:00:00 发表: 需要版面费吗, beContent=多巴胺受体 2018-09-21 00:00:00 发表: 需要版面费吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ba5226495, createdName=努力的科研小白, createdTime=Sat Nov 16 00:00:00 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562383, encodeId=9f4e562383a0, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：10月23日晚上投的，10月25日下午被拒，理由是不再接收meta 分析类的。编辑挺友好地给回的邮件告知，做meta 的朋友就不必尝试了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKJ73fWSxHh3xvG6CRmkSC454TlmZGCL5nXyJYuwwrvJtX7y37Q0W3jVTNKAXJvK0cZlXW85O4BdQ/132, createdBy=13532450097, createdName=王尛象, createdTime=Thu Oct 25 00:00:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561326, encodeId=ce2f56132633, content=需要版面费吗wgwang2003092 2016-08-20 22:19:00 发表: 投了一篇综述，审稿很快，审稿专家很友好！网刊更快！, beContent=wgwang2003092 2016-08-20 22:19:00 发表: 投了一篇综述，审稿很快，审稿专家很友好！网刊更快！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=287, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaELE8BUMzWSJdUBRwxgHrxk2iaPIB0NY8bDTJuSKseW0DVGuc7TAlMgB07cRxUAgPGp75ibOO3ItpezQ/132, createdBy=876d2299966, createdName=多巴胺受体, createdTime=Fri Sep 21 00:00:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=557427, encodeId=f52255e4276d, content=您好.想请教一下这个期刊的***址.找不到链接呀Lijia 2017-11-23 19:54:00 发表: 以下来自官网 Journal of Cardiovascular Pharmacology and Therapeutics 2016 Impact Factor: 3.000 2016 Ranking: 88/256 in Pharmacology & Pharmacy | 52/126 in Cardiac & Cardiovascular Systems Source: 2016 Journal Citation Reports? (Clarivate Analytics, 2017); Indexed in PubMed: MEDLINE, beContent=Lijia 2017-11-23 19:54:00 发表: 以下来自官网 Journal of Cardiovascular Pharmacology and Therapeutics 2016 Impact Factor: 3.000 2016 Ranking: 88/256 in Pharmacology & Pharmacy | 52/126 in Cardiac & Cardiovascular Systems Source: 2016 Journal Citation Reports? (Clarivate Analytics, 2017); Indexed in PubMed: MEDLINE, objectType=tool_impact_factor, channel=null, level=null, likeNumber=332, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a0e2229174, createdName=2453381967_77778861, createdTime=Thu May 31 00:00:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549434, encodeId=724c549434f3, content=以下来自官网 Journal of Cardiovascular Pharmacology and Therapeutics 2016 Impact Factor: 3.000 2016 Ranking: 88/256 in Pharmacology & Pharmacy | 52/126 in Cardiac & Cardiovascular Systems Source: 2016 Journal Citation Reports? (Clarivate Analytics, 2017); Indexed in PubMed: MEDLINE, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=366, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzXGyEIGjicRkpC7Ba3cAvgGcQ4lPPPHiagY3uGMDwl0amJesCO4IgzNdibia7ibjN2QU7JbIE3OrKxsIw/0, createdBy=a2411983122, createdName=Lijia7873, createdTime=Thu Nov 23 19:54:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549100, encodeId=ba87549100e0, content=不要版免费叶子12 2017-06-17 发表:: 研究方向：心血管; 各位朋友，您们好，我准备往这份杂志投一篇Meta分析，由于我还是一名在校研究生，没经费持续，所以想问问知道的朋友，该杂志是否免投稿的版面费呀？谢谢了，不胜感激，祝工作节节高升。发越来越多的SCI。, beContent=叶子12 2017-06-17 发表:: 研究方向：心血管; 各位朋友，您们好，我准备往这份杂志投一篇Meta分析，由于我还是一名在校研究生，没经费持续，所以想问问知道的朋友，该杂志是否免投稿的版面费呀？谢谢了，不胜感激，祝工作节节高升。发越来越多的SCI。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=324, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K6oaIJIATXp29Oic3Mpd57m5mOn1MrF2MZlGT1kqZETYTNGibicBD6OiclKRANUZyt3NJJJBb8kvU30k/0, createdBy=ccd61735665, createdName=wxsession50e170d4, createdTime=Sat Nov 11 02:11:00 CST 2017, time=2017-11-11, status=1, ipAttribution=)]

2017-11-23 Lijia7873

以下来自官网
Journal of Cardiovascular Pharmacology and Therapeutics
2016 Impact Factor: 3.000
2016 Ranking: 88/256 in Pharmacology & Pharmacy | 52/126 in Cardiac & Cardiovascular Systems
Source: 2016 Journal Citation Reports? (Clarivate Analytics, 2017); Indexed in PubMed: MEDLINE

366 0

[GetPortalCommentsPageByObjectIdResponse(id=1092669, encodeId=de3010926697c, content=我是写那种格式的摘要比较好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092670, encodeId=030210926e030, content=摘要一般有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068169, encodeId=9c74106816911, content=偏重的研究方向：心血管;药物治疗 经验分享：请问这个杂志接受基础类研究吗？药物机制之类的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3e5463292, createdName=ms9000000616654220, createdTime=Mon Nov 08 17:13:16 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585267, encodeId=e24b58526e82, content=您好，请问您知道心血管类的网状meta分析应该投哪个杂志吗？王尛象 2018-10-25 00:00:00 发表: 10月23日晚上投的，10月25日下午被拒，理由是不再接收meta 分析类的。编辑挺友好地给回的邮件告知，做meta 的朋友就不必尝试了。, beContent=王尛象 2018-10-25 00:00:00 发表: 10月23日晚上投的，10月25日下午被拒，理由是不再接收meta 分析类的。编辑挺友好地给回的邮件告知，做meta 的朋友就不必尝试了。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=511d5270481, createdName=1482027dm93暂无昵称, createdTime=Mon Feb 24 00:00:00 CST 2020, time=2020-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579938, encodeId=17915e993842, content=请问需要版面费吗？多巴胺受体 2018-09-21 00:00:00 发表: 需要版面费吗, beContent=多巴胺受体 2018-09-21 00:00:00 发表: 需要版面费吗, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ba5226495, createdName=努力的科研小白, createdTime=Sat Nov 16 00:00:00 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562383, encodeId=9f4e562383a0, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：10月23日晚上投的，10月25日下午被拒，理由是不再接收meta 分析类的。编辑挺友好地给回的邮件告知，做meta 的朋友就不必尝试了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKJ73fWSxHh3xvG6CRmkSC454TlmZGCL5nXyJYuwwrvJtX7y37Q0W3jVTNKAXJvK0cZlXW85O4BdQ/132, createdBy=13532450097, createdName=王尛象, createdTime=Thu Oct 25 00:00:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561326, encodeId=ce2f56132633, content=需要版面费吗wgwang2003092 2016-08-20 22:19:00 发表: 投了一篇综述，审稿很快，审稿专家很友好！网刊更快！, beContent=wgwang2003092 2016-08-20 22:19:00 发表: 投了一篇综述，审稿很快，审稿专家很友好！网刊更快！, objectType=tool_impact_factor, channel=null, level=null, likeNumber=287, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaELE8BUMzWSJdUBRwxgHrxk2iaPIB0NY8bDTJuSKseW0DVGuc7TAlMgB07cRxUAgPGp75ibOO3ItpezQ/132, createdBy=876d2299966, createdName=多巴胺受体, createdTime=Fri Sep 21 00:00:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=557427, encodeId=f52255e4276d, content=您好.想请教一下这个期刊的***址.找不到链接呀Lijia 2017-11-23 19:54:00 发表: 以下来自官网 Journal of Cardiovascular Pharmacology and Therapeutics 2016 Impact Factor: 3.000 2016 Ranking: 88/256 in Pharmacology & Pharmacy | 52/126 in Cardiac & Cardiovascular Systems Source: 2016 Journal Citation Reports? (Clarivate Analytics, 2017); Indexed in PubMed: MEDLINE, beContent=Lijia 2017-11-23 19:54:00 发表: 以下来自官网 Journal of Cardiovascular Pharmacology and Therapeutics 2016 Impact Factor: 3.000 2016 Ranking: 88/256 in Pharmacology & Pharmacy | 52/126 in Cardiac & Cardiovascular Systems Source: 2016 Journal Citation Reports? (Clarivate Analytics, 2017); Indexed in PubMed: MEDLINE, objectType=tool_impact_factor, channel=null, level=null, likeNumber=332, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a0e2229174, createdName=2453381967_77778861, createdTime=Thu May 31 00:00:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549434, encodeId=724c549434f3, content=以下来自官网 Journal of Cardiovascular Pharmacology and Therapeutics 2016 Impact Factor: 3.000 2016 Ranking: 88/256 in Pharmacology & Pharmacy | 52/126 in Cardiac & Cardiovascular Systems Source: 2016 Journal Citation Reports? (Clarivate Analytics, 2017); Indexed in PubMed: MEDLINE, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=366, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzXGyEIGjicRkpC7Ba3cAvgGcQ4lPPPHiagY3uGMDwl0amJesCO4IgzNdibia7ibjN2QU7JbIE3OrKxsIw/0, createdBy=a2411983122, createdName=Lijia7873, createdTime=Thu Nov 23 19:54:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549100, encodeId=ba87549100e0, content=不要版免费叶子12 2017-06-17 发表:: 研究方向：心血管; 各位朋友，您们好，我准备往这份杂志投一篇Meta分析，由于我还是一名在校研究生，没经费持续，所以想问问知道的朋友，该杂志是否免投稿的版面费呀？谢谢了，不胜感激，祝工作节节高升。发越来越多的SCI。, beContent=叶子12 2017-06-17 发表:: 研究方向：心血管; 各位朋友，您们好，我准备往这份杂志投一篇Meta分析，由于我还是一名在校研究生，没经费持续，所以想问问知道的朋友，该杂志是否免投稿的版面费呀？谢谢了，不胜感激，祝工作节节高升。发越来越多的SCI。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=324, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K6oaIJIATXp29Oic3Mpd57m5mOn1MrF2MZlGT1kqZETYTNGibicBD6OiclKRANUZyt3NJJJBb8kvU30k/0, createdBy=ccd61735665, createdName=wxsession50e170d4, createdTime=Sat Nov 11 02:11:00 CST 2017, time=2017-11-11, status=1, ipAttribution=)]

2017-11-11 wxsession50e170d4

不要版免费叶子12 2017-06-17 发表::
研究方向：心血管; 各位朋友，您们好，我准备往这份杂志投一篇Meta分析，由于我还是一名在校研究生，没经费持续，所以想问问知道的朋友，该杂志是否免投稿的版面费呀？谢谢了，不胜感激，祝工作节节高升。发越来越多的SCI。

叶子12 2017-06-17 发表:: 研究方向：心血管; 各位朋友，您们好，我准备往这份杂志投一篇Meta分析，由于我还是一名在校研究生，没经费持续，所以想问问知道的朋友，该杂志是否免投稿的版面费呀？谢谢了，不胜感激，祝工作节节高升。发越来越多的SCI。

324 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务